



03-22-01

CAU 1647
#4
11/6/01

Express Mail No.: EL 501 638 098 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Morré and Morré

Application No.: 09/536,551

Filed: March 28, 2000

For: METHODS FOR IDENTIFYING
AGENTS THAT INHIBIT SERUM
AGING FACTORS AND USES AND
COMPOSITIONS THEREOF

Group Art Unit: 1647

Examiner: To Be Assigned

Attorney Docket No.: 8951-124-999

RECEIVED
MAR 23 2001

TECH CENTER 1600/2900

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, attorneys for Applicants hereby direct the Examiner's attention to references DO to EA listed on the attached revised form PTO 1449. Legible copies of references DO to EA are submitted herewith.

Identification of the above-listed references are not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since that form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "Revised Form PTO 1449" entitled "List of References Cited." Applicants respectfully request that the Examiner review the references cited on the attached revised PTO Form 1449, and that the references are made of record in the file history of the instant application.

Pursuant to 37 C.F.R. § 1.97(e), it is hereby stated that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Applicants estimate that no fee is required. However, should the Patent Office that a fee is required, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date March 21, 2001

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

By: Maria E. Pasquale 38,265
Maria E. Pasquale (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure